Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment

NCT02182024 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Insufficiency

Interventions

DRUG: Dabigatran etexilate high dose
DRUG: Dabigatran etexilate low dose

Sponsor

Boehringer Ingelheim